Document is current
Any future updates will be listed below
-
Authors
Zeng, Hui
Gu, Shanzhi
Guo, Yabing
Li, Hailiang
Liu, Jingfeng
Liu, Jibing
Huang, Ming
Zou, Yinghua
Liu, Ting
Wang, Zhongmin Maxwell
Li, Baiyong
Xia, Michelle Y.
Shao, Guoliang https://orcid.org/0009-0009-6962-7358
- License Information
-
More Information
Article History
Received: 19 December 2025
Accepted: 27 July 2026
First Online: 13 August 2026
Declarations
Ethics approval and consent to participate: The trial protocol was approved by the Ethics Committee of Zhejiang Cancer Hospital (approving institution: Zhejiang Cancer Hospital; approval number: IRB-[2022]373), The procedures performed in this study were in accordance with the Declaration of Helsinki and local laws. All patients provided written informed consent before undergoing any study-specific procedures.
Consent for publication: All clinical data included in this study have been fully anonymized, and no individual participant can be identified in any part of the article or supplementary materials.
Competing interests: TL, ZMW, BL and MYX are Akeso Biopharma employees. No other disclosures were reported.
